This week: synchrotron funding, astronauts returning to Earth and a chance at loan repayment
In depth: The Biden administration’s introduction of centralised price negotiations for prescription drugs will negatively affect pharmaceutical research as well as patients, the drug industry has warned.
Full story: Industry in uproar over Democrats’ drug pricing move
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.